Type 2 diabetes protection with semaglutide
Weekly injections of drug used to treat obesity cut risk in half Type-2-Diabetes develop. The drug, already approved in the US and Europe for the treatment of obesity, could help reduce the rise in obesity and diabetes worldwide.
In a new study involving experts from University of Alabama at Birmingham (UAB) investigated how drug treatment Semaglutide at risk for type 2 diabetes. The results of the study will be presented at the annual meeting European Association for the Study of Diabetes (EASD) in Stockholm.
Obesity increases the risk of type 2 diabetes
According to the researchers, it is already known that obesity development risk Type-2-Diabetes at least for this Magnified six times. Therefore, it was reasonable to conclude that medical treatment of obesity may also reduce the risk of developing diabetes.
To test this, the team investigated whether the drug semaglutide could reduce the risk of developing type 2 diabetes. It is approved by the US Food and Drug Administration (FDA).FDA) is already approved in the US for the treatment of obesity.
In the UK, according to the National Institute for Health and Care Quality (GREAT) is pre-approved and the drug has also been on the German market since 2018.
Based on an analysis of two studies that used semaglutide, its effect on the risk of developing diabetes should now be tested.
Semaglutide study design
In the first study, called STEP1 experts, 1961 member if overweight or obese, one injection weekly for 68 weeks 2.4 mg semaglutide. There was also a control group that received only a placebo.
Another survey completed (STEP 4) included a general 803 members overweight or obese. They were injected 2.4 mg semaglutide controlled. After this period, participants either continued treatment with semaglutide or received a placebo for 48 weeks.
The researchers also report that participants in both studies also received advice on diet and exercise.
Type 2 Diabetes Risk Calculation
He became the so-called Staging of cardiometabolic diseases (CMDS) is used to measure the risk of developing type 2 diabetes during the next ten years predict. According to the researchers, in the past this method has already proven to be a very accurate measure of the risk of developing type 2 diabetes.
Cardiometabolic disease staging uses a formula to calculate the risk of type 2 diabetes that includes sex, age, race, body mass index (BMI) and blood pressure, blood glucose, HDL cholesterol, and triglyceride levels of participants. .
61 percent lower risk of developing diabetes
According to the researchers, the results of the first evaluated study (STEP 1) show that participants who Semaglutide were at risk of developing type 2 diabetes over the next ten years. 61 percent decreases (from 18.2% at week 0 to 7.1% at week 68).
On the other hand, taking placebo only reduced risk of type 2 diabetes 13 percent the reasons. The risk values also reflect the weight loss experienced by the participants.
So, semaglutide resulted in moderate weight loss. 17 percent and administration of a placebo for weight loss three percent managed.
Even for members who are already prediabetes showed that the risk was reduced to the same extentthe team reports.
Reducing the risk of diabetes within 20 weeks
In the second evaluation study (STEP 4), investigators were also able to observe a reduction in diabetes risk scores with semaglutide (from 20.6% at week 0 to 11.4 percent at week 20).
If semaglutide was continued beyond week 20, the risk value was reduced to 7.7 percentwhile switching to placebo increases the risk 15.4 percent according to the researchers.
According to experts, the results indicate that ongoing treatment with semaglutide required to maintain a reduced risk of type 2 diabetes.
Significantly reduced risk of type 2 diabetes
„Semaglutide reduces the future risk of developing diabetes in obese patients by more than 60 percent, a number that is the same regardless of whether the patient has prediabetes or normal blood sugar levels.explains the author of the study. Dr. W. Timothy Garvey in one Press release.
However, according to the doctor, in order to maintain the effectiveness of the drug in protecting against type 2 diabetes, it is necessary to continue treatment with semaglutide. Nonetheless, “Semaglutide claims to be the most effective drug to date for the treatment of obesity and helps close the weight gap after bariatric surgery.“, So Dr. Garvey.
The approval of the drug is based on the results of clinical studies showing that it can be used in conjunction with a healthy lifestyle program. average weight loss background more than 15 percent leads.
„This weight loss is sufficient to treat or prevent a wide range of obesity-related complications that affect health and quality of life, and is a game-changer in obesity medicine.” sums up Dr. Garvey. (as)
Information about the author and source
This text complies with the requirements of specialized medical literature, medical guidelines and current research and has been verified by medical professionals.
- US Food and Drug Administration: FDA approves new drug for chronic weight loss for the first time since 2014 (veröffentlicht 06/04/2021), FDA
- National Institute for Health and Excellence: NICE recommends new drug for people living with obesity (veröffentlicht 02/08/2022), GREAT
- Diabetology: study shows revolutionary obesity drug more than halves risk of developing type 2 diabetes (veröffentlicht 09/11/2022), Diabetology
This article contains general advice only and should not be used for self-diagnosis or treatment. It cannot replace a visit to the doctor.